Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent

• Published in: Neurourology and urodynamics 2001, Vol.20 (2), p.157-165
• Main Authors: Bent, Alfred E., Tutrone, Ronald T., McLennan, Mary T., Lloyd, Keith, Kennelly, Michael J., Badlani, Gopal
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Chondrocytes; collagen injection therapy; Ear, External - cytology; Female; Humans; intrinsic sphincter deficiency (ISD); Middle Aged; periurethral bulking; stress incontinence; Urinary Incontinence, Stress - therapy
• ISSN: 0733-2467; 1520-6777
• DOI: 10.1002/1520-6777(2001)20:2<157::AID-NAU18>3.0.CO;2-A

Intrinsic sphincter deficiency (ISD) is frequently treated with collagen bulking at the bladder neck. The standard material used, Contigen, biodegrades over 3–19 months requiring repeated injections to maintain efficacy. The study objective was to evaluate use of autologous ear chondrocytes for treatment of ISD. Women with documented ISD had harvest of auricular cartilage. Chondrocytes were isolated from the cartilage and expanded in culture and formulated with calcium alginate to form an injectable gel. Thirty‐two patients received a single outpatient injection just distal to the bladder neck. Outcome measures included voiding diary, quality‐of‐life scores, incontinence severity grading, and pad weight testing. Incontinence grading indicated 16 patients dry, and 10 improved at 12 months for a total of 26 of 32 (81.3%) dry and improved after one treatment. Only four patients had a 12‐month pad weight test over 2.2 g. Quality‐of‐life scores improved significantly after treatment. There was a decrease in incontinence impact scores in all categories. The urogenital distress inventory declined for all categories except bladder emptying and lower abdominal pain. Endoscopic treatment of ISD with autologous chondrocytes is safe, effective, and durable with 50 % of patients dry 12 months after one injection. Twenty‐six of 32 patients dry or improved at 3 months after the injection maintained the effect at the 12‐month visit. Neurourol. Urodynam. 20:157–165, 2001. © 2001 Wiley‐Liss, Inc.